SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: quidditch who wrote (3150)6/2/1999 12:22:00 PM
From: Biomaven  Read Replies (2) of 10280
 
steven,

I don't even know if the FTC has anything to do with a deal for a foreign market - I would guess not in this case.

I very much doubt that the deal excluded the US because of the FTC issue - much more likely it has to do with the PFE co-marketing agreement that UBC has in the US. Three-way deals are always more complicated.

This deal does put some pressure on PFE to do a similar deal with SEPR for the US rights. Be very interesting to see if the UBC/SEPR deal gives SEPR the right to use the UBC clinical data in a US NDA application.

Zyrtec has the reputation of being the most effective of the non-sedating antihistamines. It's drawback is that it's also the most sedating - in fact I don't think its label lets it be called non-sedating. If the SEPR ICE maintains effectiveness and loses the sedation, it could be a very big player if PFE markets it.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News